The NDA includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.:
Source: Neurology Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
Related Posts
<![CDATA[Phase 4 Study Evaluates Direct
IVIg-to-Efgartigimod Transition in CIDP Without Disease Worsening
Requirement]]>
<![CDATA[Phase 4 Study Evaluates Direct IVIg-to-Efgartigimod Transition in CIDP Without Disease Worsening Requirement]]>
